Navigation Links
Drug Firm Disowns Liability

The German biotech firm TeGenero, the drugs company behind the clinical trial listed its potential side effects on its 12-page document prepared by Parexel. //This consent form listed a side effect which can seriously harm the immune system. The clinical trial left six volunteers fighting for their lives. The consent form the men were asked to sign, which has been obtained by The Observer, warned that a possible effect of the drug was cytokine release. This includes a massive immune reaction to a chemical as it triggers an uncontrollable response from antibodies.

It is otherwise called as a cytokine release or cytokine storm. This can be life-threatening but the form does not spell that out. It is also doubtful whether the doctor heading the trial at Northwick Park Hospital in north London verbally highlighted the specific nature of the cytokine risk to the participants. The form says that that the drug could cause a hives-like allergic reaction. The volunteers were struck down with symptoms within minutes of being injected with the drug. A string of possible side effects are listed on the form, revealed for the first time in this newspaper. The consent form says that the participants may not experience any side effects as the doses used in early human studies are always very small.

But sometimes unintended effects may be encountered during any trial with a monoclonal antibody drug, though they did not occur even at the highest tested doses in animals. The various side effects listed are immunosuppression, autoimmunity, cytokine release, and anaphylaxis. Even the Medicines and Healthcare Products Regulatory Agency (MHRA) which authorised the trial was notified beforehand that there was this risk of cytokine release. The study obtained approval from German and UK authorities.


'"/>




Page: 1

Related medicine news :

1. Ex-workers Ask HLL to Accept Liability for Mercury Deaths
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at Palm ... , will be taking part in the 2017 London Marathon. Set to take place on ... of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, raising ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: